For adults with type 2 diabetes and obesity, glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with a lower risk for dementia, stroke, and all-cause mortality compared with other ...

Landmark trials have shown that GLP-1 receptor agonists, originally developed for diabetes and weight loss, also provide ...

For adults with type 2 diabetes and obesity, glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with a lower risk for dementia, stroke, and all-cause mortality compared with other ...

For patients with type 2 diabetes, GLP-1 RAs are associated with an increased risk for GERD compared with SGLT-2 inhibitors.

While many believe the agents to be potential game changers, evidence is still lacking in psoriatic disease, and experts urge ...

Q: I’m trying to improve my nutrition, but it’s not easy. Can you help me feel more motivated, please? — Jenny T., Evanston, Ill.

For patients with idiopathic intracranial hypertension (IIH), glucagon-like peptide 1 receptor agonist (GLP-1 RA) treatment ...

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes management.

Individuals with type 2 diabetes who receive treatment with GLP-1 RAs do not have an increased risk for acute pancreatitis.

GLP-1 receptor agonists such as semaglutide and liraglutide promote significant weight loss and improved glycemic control, ...

GLP-1 drugs, which have seen widespread success, have been linked to a number of cases of pancreatitis in the UK, which have led to hospitalisations and even deaths.